Armistice Capital LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Armistice Capital LLC increased its holdings in Regeneron Pharmaceuticals by 306.7% in the first quarter, owning 114,073 shares valued at approximately $72.35 million.
• Regeneron Pharmaceuticals reported a net margin of 31.37% and earnings per share of $12.89, exceeding analysts' expectations significantly during its latest earnings release.
• The company announced a quarterly dividend of $0.88 per share, resulting in an annualized dividend yield of 0.6%.

Armistice Capital LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 306.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 114,073 shares of the biopharmaceutical company's stock after buying an additional 86,028 shares during the period. Regeneron Pharmaceuticals comprises about 1.1% of Armistice Capital LLC's investment portfolio, making the stock its 10th biggest holding. Armistice Capital LLC owned 0.10% of Regeneron Pharmaceuticals worth $72,349,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of REGN. Brighton Jones LLC boosted its stake in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. American Assets Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $427,000. Aspire Growth Partners LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $421,000. Aptus Capital Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 64.2% during the 4th quarter. Aptus Capital Advisors LLC now owns 1,599 shares of the biopharmaceutical company's stock valued at $1,139,000 after purchasing an additional 625 shares in the last quarter. Finally, Bellevue Group AG raised its holdings in shares of Regeneron Pharmaceuticals by 17.3% during the 4th quarter. Bellevue Group AG now owns 31,412 shares of the biopharmaceutical company's stock valued at $22,376,000 after purchasing an additional 4,636 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $3.42 during trading on Thursday, hitting $567.22. The stock had a trading volume of 996,247 shares, compared to its average volume of 1,100,976. The firm has a market cap of $60.12 billion, a PE ratio of 14.29, a P/E/G ratio of 1.93 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,175.16. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a 50 day simple moving average of $560.61 and a 200-day simple moving average of $586.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm posted $11.56 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on REGN shares. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Finally, Morgan Stanley restated an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.